Jury awards $332 million to Carlsbad man who blamed his cancer on Roundup weedkiller
A jury has awarded $332 million to a Carlsbad man who sued chemical giant Monsanto on the grounds that his cancer was related to decades of using its Roundup weedkiller.
A San Diego Superior Court jury awarded the damages Tuesday in a lawsuit filed by Mike Dennis, 57, who was diagnosed in 2020 with a rare form of non-Hodgkin’s lymphoma.
His lawsuit contended that his illness was related to Roundup’s active ingredient, glyphosate.
Dennis had treatment and has been in remission for nearly three years, but there is no cure, Adam Peavy, one of his attorneys, told KNSD-TV.
“His doctors have told him it’s going to come back, and we’re just waiting to see if that happens,” Peavy said.
The jury found that Monsanto, which is now a division of pharmaceutical and biotechnology giant Bayer, failed to provide warnings of Roundup’s risks. But jurors also ruled partially in Bayer’s favor by finding that the product design wasn’t defective and the company wasn’t negligent.
Supreme Court rejects Bayer’s bid to stop thousands of suits, including a $25-million judgment for a California man, claiming Roundup causes cancer.
Dennis was awarded $7 million in compensatory damages and $325 million in punitive damages.
In a statement to KNSD-TV, Bayer said it believes that “we have strong arguments on appeal to get this unfounded verdict overturned and the unconstitutionally excessive damage award eliminated or reduced.”
“There were significant and reversible legal and evidentiary errors made during this trial,” Bayer added.
Bayer bought Monsanto for $63 billion in 2018 and has been trying to deal with thousands of claims and lawsuits related to Roundup. In 2020, Bayer announced that it would pay up to $10.9 billion to settle some 125,000 filed and unfiled claims.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.
